The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
BUSINESS
US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
Mitsubishi Tanabe Pharma said that the US FDA has awarded seven years of orphan drug exclusivity for its oral suspension version of the ALS therapy Radicava (edaravone), Radicava ORS. The designation was granted on March 28. Radicava ORS is a…
To read the full story
Related Article
- Oral Radicava Approved in Switzerland: Mitsubishi Tanabe
May 12, 2023
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- US FDA OKs Mitsubishi Tanabe’s Oral Edaravone for ALS
May 16, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for Swiss Review in ALS
April 26, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for FDA Review in ALS
January 14, 2022
- Mitsubishi Tanabe Eyes US Submission of Oral Edaravone by March-End
December 13, 2021
BUSINESS
- Leqembi’s FY2024 Sales at 44.3 Billion Yen: Eisai
May 7, 2025
- Lilly’s Eczema Drug Ebglyss Now Available for Self-Injection
May 7, 2025
- Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
May 7, 2025
- Satsuma’s Nasal Powder Drug for Migraine Approved in US
May 7, 2025
- Otsuka's Profit Might Drop by Billions if US Imposes 25% Tariff
May 7, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…